China's biological influenza virus split vaccine has passed WHO pre certification

Tech 2023-10-21 16:18:42 Source: Network

According to the official WeChat account of China Biotech, on October 20, 2023, the influenza virus split vaccine produced by China National Pharmaceutical Group Changchun Institute of Biological Products passed the pre certification of the World Health Organization (WHO). As the first influenza vaccine in China to pass the pre certification of the World Health Organization, it marks that the production, manufacturing, and quality management level of China's biological influenza vaccine has been at the forefront of the world

According to the official WeChat account of China Biotech, on October 20, 2023, the influenza virus split vaccine produced by China National Pharmaceutical Group Changchun Institute of Biological Products passed the pre certification of the World Health Organization (WHO). As the first influenza vaccine in China to pass the pre certification of the World Health Organization, it marks that the production, manufacturing, and quality management level of China's biological influenza vaccine has been at the forefront of the world. Not only has China made outstanding contributions to domestic influenza prevention and control, but also contributed to building a global health barrier.

The influenza virus split vaccine produced by Changchun Institute of Biological Products has officially launched the pre certification work of the World Health Organization since 2015, and has undergone comprehensive and in-depth benchmarking with the latest international regulations and guidelines. After process changes and continuous optimization, the product quality standards have been continuously improved. In September 2018, the pre certification application materials of the World Health Organization were submitted; And complete on-site inspection in 2022.

The influenza virus split vaccine produced by Changchun Institute of Biological Products is made by inoculating chicken embryos with epidemic strains recommended by the World Health Organization. After cultivation, harvesting of virus solution, virus purification, splitting, re purification, and inactivation, it is produced. Its production process is stable, and the production process is always under control. It can continuously produce influenza vaccines with good consistency, and all quality standards are higher than those of the Chinese Pharmacopoeia and European Pharmacopoeia, fully ensuring the quality, safety, and effectiveness of influenza vaccines.

Editor Liu Jiani

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: China biological influenza virus split vaccine has passed WHO